LISATA THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
LISATA THERAPEUTICS, INC. (LSTA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$23.87 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2019-03-14
- LISATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was -$7.56M.
- LISATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was -$2.71M.
- LISATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was -$23.87M, a 222.64% decline from fiscal 2017.
- LISATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was $19.46M.
- LISATA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2016 was -$5.61M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | -$23.87M 10-K · filed 2019-03-14 | ||||
| 2018-09-30 | -$19.79M 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | -$11.44M 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | -$7.56M 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $19.46M 10-K · filed 2019-03-14 | $19.46M 10-K · filed 2018-03-22 | |||
| 2017-09-30 | $5.38M 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | $13.34M 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | -$2.71M 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | -$5.61M 10-K · filed 2018-03-22 | ||||
| 2016-09-30 | -$1.71M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |